# Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

> **NCT03469258** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Pancrelipase

## Key facts

- **NCT ID:** NCT03469258
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-13
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsorship for trial was halted after company acquisition
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469258, "Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03469258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*